North America Autoimmune Disease Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

North America Autoimmune Disease Diagnostics Market Analysis

The North America Autoimmune Disease Diagnostics Market size is estimated at USD 2.05 billion in 2024, and is expected to reach USD 2.68 billion by 2029, growing at a CAGR of 5.53% during the forecast period (2024-2029).

• The COVID-19 pandemic significantly impacted market growth, as there were increased complications of COVID-19 associated with various autoimmune diseases such as rheumatoid arthritis and type 1 diabetes, among others. For instance, according to an article published by the Lancet Discovery Science in January 2023, a study was conducted in the United States which showed COVID-19 infected patients had significantly higher risks of autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, dermatopolymyositis, and systemic sclerosis among others.
• Thus, the COVID-19 pandemic had a significant impact on the market during the initial phase; however, as the pandemic has subsided, the studied market is expected to have average growth during the forecast period of the study.
• The rising prevalence of autoimmune diseases and growing public awareness of autoimmune disorders is the primary factor driving the market growth. For instance, according to the data updated by the National Psoriasis Foundation of the United States in December 2022, it was estimated that more than 8 million Americans were living with psoriasis in the United States in 2021. An estimated 30% of people living with psoriasis are also expected to develop psoriatic arthritis, and the psoriasis prevalence in African Americans is estimated to be 1.5% compared to 3.6% in Caucasians.
• Thus, the high prevalence of autoimmune diseases such as psoriasis is expected to boost the adoption of autoimmune disease diagnostics. Furthermore, according to data updated by the Canadian Association of Psoriasis Patients in June 2021, psoriasis is considered a common, chronic, and disabling skin disease affecting about 1 million Canadians. Hence, the region's high prevalence of such autoimmune diseases is expected to boost the market growth.
• Moreover, increasing developments by major market players in the region are also expected to boost market growth, enabling patients to have diversified access to various products. For instance, in August 2021, the United States Food and Drug Administration (FDA) approved Thermo Fisher Scientific's blood test for diagnosing systemic lupus erythematosus (SLE) autoimmune disorder. The EliA SmDP-S test reduces the number of false-positive results and provides improved diagnostic guidance for the disease.
• Hence, the factors above, such as the high prevalence of autoimmune disorders such as psoriasis, among others, and the rising developments by major market players, are expected to boost the market growth. However, the slow turnaround time for autoimmune disease diagnostic test results and the high frequency of false positive results are expected to impede the market growth.

North America Autoimmune Disease Diagnostics Market Trends

Immunologic Assays Segment is Expected to Hold a Significant Market Share Over the Forecast Period

North America Autoimmune Disease Diagnostics Industry Segmentation

As per the scope of the report, autoimmunity involves the loss of normal immune homeostasis, as the organism produces an abnormal response to its own tissue. Autoimmune diseases generally involve the presence of self-reactive T cells, autoantibodies, and inflammation. The diagnosis can be useful in the management of patients suffering from autoimmune diseases and help in providing a prognosis or indicating the severity of organ involvement or damage. 

The North American autoimmune disease diagnostics market is segmented by disease type (systemic autoimmune disease (rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), multiple sclerosis, and other disease types) and localized autoimmune disease(inflammatory bowel disease, type 1 diabetes, thyroid, and other localized autoimmune diseases)), diagnosis tests (regular laboratory tests, inflammatory markers, immunologic assays, antibody tests, and other tests), and geography (United States, Canada, and Mexico). 

The report offers the value (in USD million) for the above segments.